Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Mecasermin in Children With GHIS/Primary IGFD
NCT00571727Phase 3Completed
- Sponsor
- Ipsen
- Start
- May 1991
- Primary completion
- Dec 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mecasermin in growth hormone insensitivity syndrome (GHIS), sponsored by Ipsen. Primary endpoints: Annualized Height Velocity Up to 12 Years and Number of Naive Participants With Height Velocity <5 cm/y at the End of 1 Year. Started May 1991; status: completed.
02
Drugs
mecasermin
03
Conditions
growth hormone insensitivity syndrome (GHIS)
Beyond the preview
Go deeper on NCT00571727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571727.